On October 29, 2026, the Department of Labor’s Employee Benefits Security Administration (EBSA) announced a final rule requiring pharmacy benefit managers (PBMs) and affiliated brokers and consultants to disclose direct and indirect compensation to fiduciaries of large, self-insured ERISA group health plans. The rule appeared in the Federal Register on November 2, 2026, at 91 FR 69092 (2026-22306).
If you administer COBRA, FSA/HSA/HRA, or consolidated billing for employers who also sponsor self-funded medical, this is not your day-to-day compliance file—but it is the kind of cross-benefit news HR teams ask about when pharmacy invoices spike. The rule sits at the intersection of ERISA fiduciary duty, Consolidated Appropriations Act, 2026 (CAA 2026) pharmacy reforms, and Executive Order 14273 on drug pricing transparency.
What changed (and who is in scope)
The regulation implements ERISA section 408(b)(2)(B) for covered service providers that contract for pharmacy benefit management services with covered plans—generally large self-insured group health plans.
Under the final rule’s definitions (aligned with ERISA section 726):
- A specified large employer means an employer that employed an average of at least 100 employees on business days during the preceding calendar year (counting rules track IRC section 4980H).
- A specified large plan is a self-insured group health plan with at least 100 participants (with special rules for multiemployer and multiple-employer plans).
Fully insured medical plans are not “covered plans” for this rule’s detailed PBM disclosure package. QSEHRAs are excluded from the ERISA group health plan definition used here. Plans established by sponsors in the drug supply chain get a tailored disclosure path to address anti-competitive concerns.
Covered service providers include PBMs and PBM-affiliated brokers or consultants that expect at least $1,000 in compensation (direct or through affiliates, agents, or subcontractors) for PBM-related services.
Key dates
| Milestone | Date | |-----------|------| | DOL announcement | October 29, 2026 | | Federal Register publication | November 2, 2026 | | Regulation effective | January 4, 2027 | | Disclosure duties apply | Plan years beginning on or after July 1, 2027 |
EBSA’s release notes a temporary enforcement policy for broader 408(b)(2)(B) disclosures that Congress amended in CAA 2026 (effective February 3, 2026): through the rule’s applicability date, the Department will not treat good-faith efforts as failures—details are in the rule preamble.
What PBMs must disclose
The final rule builds on the January 30, 2026 proposal (RIN 1210-AB37) and harmonizes it with CAA 2026 amendments to 408(b)(2) and new ERISA section 726 reporting.
For covered plans, covered service providers owe initial and ongoing written disclosures so fiduciaries can judge whether contracts are reasonable and compensation is no more than reasonable—the classic 408(b)(2) prohibited-transaction exemption conditions.
Initial disclosures must arrive before the plan enters into, extends, or renews a PBM contract. For extensions and renewals, 90 days in advance is treated as reasonable (parties can negotiate more time).
Disclosures must describe, among other items:
- Services the PBM (and affiliates) will perform.
- Direct compensation from the plan or sponsor, by service and in total.
- Indirect compensation tied to drug spending, including:
- Manufacturer payments (rebates, fees, alternative discounts, and similar remuneration), including what passes to the plan versus what the PBM retains. - Spread compensation—the difference between what the plan pays the PBM and what the PBM pays pharmacies—by drug and channel. - Pharmacy recoupments (copay clawbacks, effective-rate reconciliations, and similar retroactive adjustments). - Price protection and inflation-protection arrangements with manufacturers.
Semiannual disclosures follow (or quarterly if the plan requests), aligned with section 726 reporting periods. Fiduciaries also receive audit rights to verify accuracy. DOL’s fact sheet summarizes the innocent fiduciary relief path when a PBM misses its disclosure obligations: notify EBSA, seek correction, document whether to continue or terminate the arrangement.
DOL’s October 29 release states the rule is projected to reduce prescription drug costs for plans and participants by up to $22 billion (undiscounted) over 10 years—treat that as agency projection, not a guarantee for any one employer.
How this differs from the 2028 rebate pass-through
CAA 2026 added a separate PBM obligation: for plan years beginning on or after August 3, 2028, 408(b)(2)(C) requires PBMs to remit 100% of manufacturer rebates, fees, alternative discounts, and similar remuneration to the plan (or issuer on the plan’s behalf). Section 726 adds detailed retrospective drug-spending reports on a semiannual or quarterly cycle for the same large self-insured universe.
The November 2026 final rule is the prospective contracting layer—initial and semiannual compensation disclosures and audit rights so fiduciaries can negotiate before and during the contract. Think of 408(b)(2) disclosures as the bid-review binder and section 726 as the after-action report starting in 2028.
What this means for TPAs and HR/benefits teams
Most TPAs (including CBA) do not administer PBM contracts or medical claims—but employers still route pharmacy questions through the same HR desk that handles COBRA and cafeteria elections.
Practical takeaways:
- Self-funded employers at or above 100 lives should put July 1, 2027 plan years on the calendar now. Renewal cycles that start in spring 2027 need 90-day disclosure lead time in RFPs and broker letters.
- Medical TPAs and benefits consultants—not the COBRA vendor—should own the 408(b)(2) checklist: confirm whether your PBM agreement names the responsible plan fiduciary, whether affiliate brokers are covered, and whether audit language matches the final rule.
- Fully insured employers get less from this specific rule, but CAA 2026 still expanded 408(b)(2)(B) to many group health plan service providers (including TPAs). DOL’s release says the final rule includes compliance-assistance for that broader statutory disclosure regime even when the detailed PBM article applies only to large self-insured plans.
- Do not confuse this with last week’s ePA news. The October 21 employer statement on electronic prior authorization for self-funded plans is voluntary market alignment; the PBM fee rule is binding ERISA regulation with a July 1, 2027 applicability date.
What employers should do now
- Confirm plan size and funding. If you are self-insured with 100+ participants or 100+ employees, assume you are in the covered plan bucket unless counsel says otherwise.
- Add PBM disclosure exhibits to 2027 renewals. Require initial disclosures 90 days before renewal, semiannual updates, and audit access in the contract—not as a side letter.
- Brief your committee or board. Pharmacy is a fiduciary decision for self-funded plans; document who reviewed spread and rebate disclosures and what they concluded about reasonable compensation.
- Watch the January 4, 2027 effective date for regulatory text changes, but operate to the July 1, 2027 plan year for actual PBM reporting duties.
- Keep welfare and medical vendors straight. Questions about HSA/FSA substantiation or COBRA premiums still belong with your account-plan administrator; PBM fee transparency belongs with your medical fiduciary team and PBM account lead.
We help Texas-area employers with COBRA, FSA/HSA/HRA administration, and consolidated billing—the account-based and continuation side of the house. If pharmacy transparency has your leadership asking for cleaner welfare-plan operations behind the scenes, contact CBA.